Study | Country | Study design | Group | Cases (n) | Age (mean (SD) or median) | BMI (mean (SD) or median) | TNM stage (I/II/II/IV) | OS (3-year or 5-year) | RFS (3-year or 5-year) | Relapse (n) | HLN ((mean (SD) or median) | Follow-up time (median (range) (M) | Quality |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gao Y 2018 | China | R | RG LG | 163 339 | 60.27 ± 10.50 59.36 ± 11.08 | 23.77 ± 3.11 23.44 ± 3.47 | 0/57/106/0 0/169/170/0 | 76.1% 81.7% | 73.0% 67.6% | 44 106 | 30.55 ± 10.13 29.34 ± 9.76 | 50.5 (36–72) | good |
Lee J 2015 | Korea | R | RG LG | 133 267 | 53.6 ± 13.2 59.2 ± 11.7 | 23.2 ± 2.7 23.7 ± 2.8 | 101/15/17/0 218/32/17/0 | 94.7% 93.2% | NA | NA | 41.2 ± 13.1 39.9 ± 13.3 | 75 (36–126) | good |
Li Z 2018 | China | R | RG LG | 125 329 | 55.4 ± 11.5 56.9 ± 10.5 | 23.7 ± 2.8 23.1 ± 3.0 | 24/51/50/0 37/127/165/0 | 78.6% 74.1% | 81.2% 78.6% | 21 24 | 29.5 ± 9.6 27.7 ± 8.7 | 28 (3–52) | good |
Nakauchi M 2016 | Japan | R | RG LG | 84 437 | 64 68 | 22.6 21.8 | 61/10/12/1 310/80/42/5 | 86.9% 88.8% | 86.9% 86.3% | 11 60 | 40 38 | 42.2 (1.7–78.9) | good |
Obama K 2017 | Japan | R | RG LG | 315 525 | 54.5 ± 12.6 59.3 ± 11.9 | 23.6 ± 3.1 23.5 ± 2.9 | 254/30/31/0 441/64/20/0 | 93.3% 91.6% | 90.7% 90.5% | 21 26 | 40.1 ± 15.4 38.6 ± 14.5 | 85 (60–114) | good |
Pugliese R 2010 | Italy | R | RG LG | 18 52 | NA | NA | All (50/8/9/3) | 78% 85% | NA | 4 8 | 25 ± 4.5 31 ± 8 | 53 (3–112) | fair |
Son T 2014 | Korea | R | RG LG | 51 58 | 55.3 ± 12.2 58.8 ± 12.2 | 22.7 ± 2.9 23.2 ± 3.3 | 35/8/8/0 43/10/5/0 | 89.5% 91.1% | 90.2%a 91.2%a | 3 3 | 47.2, 42.8 | 70 (24–112) | good |
Zhou J 2014 | China | R | RG LG | 120 394 | 54.7 55.6 | 21.6 ± 2.8 21.7 ± 2.6 | 29/36/55/0 115/98/181/0 | 67.8% 69.9% | NA | 5 28 | 34.6 ± 10.9 32.7 ± 11.2 | 17 (3–41) | good |